-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is worth noting that the immune system of patients after organ transplantation has caused problems in the defense of external organs, making them need to be treated with immunosuppressants.
refore, chronic rejection and chronic immunosuppression of long-term complications (e.g. infection, malignant tumors, cardiovascular disease, etc.) are the key points to be solved, people are constantly looking for new treatment strategies.
October 21, 2020, BMJ published a study by the Petra Reinke team at The University of Berlin in Berlin, Germany, entitled "Regulatory T cells for minimizer i suppression in transplantation: phase I/IIa clinicaltrial", which found that naturally regulated T-cells (nTreg) reduced immunosuppressant dosage in patients after kidney transplantation.
DOI: 10.1136/bmj.m3734 Previous studies have found that nTreg has therapeutic effects in post-organ transplant patients.
In this study, the researchers applied autolognation CD4, CD25, and FoxP3, nTreg to 11 patients who received a kidney transplant to observe its safety and ability, and to assess whether nTreg could reduce the amount of immunosuppressants in patients within 48 weeks of transplantation.
the safety of nTreg therapy after the use of immunosuppressants in patients after self-infusion minimized kidney transplantation.
dose-dependent toxicity was not found in all 3 nTreg treatment groups.
survival rate was 100% after allogeneic transplantation in the nTreg treatment group and the control group, and no serious adverse reaction events were reported.
the patients in the nTreg treatment group and the control group performed biomarker analysis on the patients, and nTreg therapy had no significant effect on other immunocell subgroups compared to the control group.
analysis of biomarkers in patients in the nTreg treatment group and control group, the study showed that the nTreg was safe, well-to-resistant, and reduced the use of immunosuppressants.
Of course, in order to further improve the efficacy and stability of the therapy, more research is needed to explore the sustainable and functional transplantation of Tregs, specificity, and resistance to immunosuppressive drugs, and to study their optimal dose.
the near future, patients with organ transplants can reduce the use of immunosuppressants and avoid their side effects by auto-transplanting immune cells.
resources: s1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .